Baxter's acquisition of Gambro, a Swedish maker of dialysis systems, for almost $4 billion has won approval from business regulators in Australia. The decision is contingent on Baxter divesting itself of its renal replacement therapy unit. The acquisition also has the green light from regulators in the U.S., Europe, Canada, Turkey, Ukraine, Brazil, South Korea and China.

Related Summaries